thalidomide has been researched along with Dysesthesia in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity." | 9.12 | Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 7.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 7.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| "There is predominance of paresthesiae in some of them while in others pain or deep sensation failure can dominate." | 5.37 | [Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. ( Bilińska, M; Kuliczkowski, K; Noga, L; Podemski, R; Potoczek, S; Szymczyk, M; Usnarska-Zubkiewicz, L, 2011) |
| "Thalidomide is effective as a first-line therapy for the treatment of multiple myeloma (MM), but its use is limited by peripheral neurotoxicity." | 5.12 | Neuropathy in multiple myeloma treated with thalidomide: a prospective study. ( Bartolomei, I; Cangini, D; Cavo, M; Michelucci, R; Pastorelli, F; Petracci, E; Plasmati, R; Salvi, F; Tacchetti, P; Tassinari, CA; Tosi, P; Zamagni, E, 2007) |
| "Thalidomide plus dexamethasone (Thal/Dex) has emerged as an effective alternative to vincristine, doxorubicin and dexamethasone as a pre-transplant induction therapy for newly diagnosed multiple myeloma." | 3.73 | Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. ( Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, S; Kyle, RA; Lacy, MQ; Lust, JA; Nowakowski, GS; Rajkumar, SV; Witzig, TE, 2005) |
| "A patient with sarcoidosis was treated with thalidomide for disfiguring and painful steroid unresponsive sarcoidal granulomas of the skin." | 3.70 | Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. ( Koblenzer, PS; Lee, JB, 1998) |
| "Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer." | 3.69 | Thalidomide-induced perioral neuropathy. ( Elad, S; Galili, D; Garfunkel, AA; Or, R, 1997) |
| "Of six patients treated with thalidomide for either prurigo nodularis or discoid lupus erythematosus, four had paresthesias in the hands and feet and one also complained of muscular pain and stiffness." | 3.67 | Thalidomide neurotoxicity. ( Andersen, KE; Clemmensen, OJ; Olsen, PZ, 1984) |
| "Thalidomide was used for graft-vs-host disease, pyoderma gangrenosum, and discoid lupus with dosages ranging from 100 to 1,200 mg/day for 5 to 16 months (cumulative dosages of 24 to 384 g)." | 2.70 | Thalidomide-induced neuropathy. ( Chaudhry, V; Cornblath, DR; Corse, A; Freimer, M; Simmons-O'Brien, E; Vogelsang, G, 2002) |
| "There is predominance of paresthesiae in some of them while in others pain or deep sensation failure can dominate." | 1.37 | [Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. ( Bilińska, M; Kuliczkowski, K; Noga, L; Podemski, R; Potoczek, S; Szymczyk, M; Usnarska-Zubkiewicz, L, 2011) |
| " The threshold neurotoxic dosage is lower than previously reported." | 1.35 | Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frankel, HC | 1 |
| Sharon, VR | 1 |
| Vleugels, RA | 1 |
| Merola, JF | 1 |
| Qureshi, AA | 1 |
| Anyanwu, CO | 1 |
| Stewart, CL | 1 |
| Werth, VP | 1 |
| Siniscalchi, A | 1 |
| Fratoni, S | 1 |
| Santeusanio, G | 1 |
| Del Poeta, G | 1 |
| de Fabritiis, P | 1 |
| Caravita, T | 1 |
| Bilińska, M | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Szymczyk, M | 1 |
| Noga, L | 1 |
| Potoczek, S | 1 |
| Kuliczkowski, K | 1 |
| Podemski, R | 1 |
| Chaudhry, V | 1 |
| Cornblath, DR | 1 |
| Corse, A | 1 |
| Freimer, M | 1 |
| Simmons-O'Brien, E | 1 |
| Vogelsang, G | 1 |
| COSTER, C | 1 |
| Dingli, D | 1 |
| Rajkumar, SV | 1 |
| Nowakowski, GS | 1 |
| Gertz, MA | 1 |
| Dispenzieri, A | 1 |
| Lacy, MQ | 1 |
| Hayman, S | 1 |
| Fonseca, R | 1 |
| Lust, JA | 1 |
| Kyle, RA | 1 |
| Greipp, PR | 1 |
| Witzig, TE | 1 |
| Plasmati, R | 1 |
| Pastorelli, F | 1 |
| Cavo, M | 1 |
| Petracci, E | 1 |
| Zamagni, E | 1 |
| Tosi, P | 1 |
| Cangini, D | 1 |
| Tacchetti, P | 1 |
| Salvi, F | 1 |
| Bartolomei, I | 1 |
| Michelucci, R | 1 |
| Tassinari, CA | 1 |
| Zara, G | 1 |
| Ermani, M | 1 |
| Rondinone, R | 1 |
| Arienti, S | 1 |
| Doria, A | 1 |
| Clemmensen, OJ | 1 |
| Olsen, PZ | 1 |
| Andersen, KE | 1 |
| Elad, S | 1 |
| Galili, D | 1 |
| Garfunkel, AA | 1 |
| Or, R | 1 |
| Lee, JB | 1 |
| Koblenzer, PS | 1 |
| Kyriakis, KP | 1 |
| Kontochristopoulos, GJ | 1 |
| Panteleos, DN | 1 |
| Fotopulos, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
3 trials available for thalidomide and Dysesthesia
| Article | Year |
|---|---|
Thalidomide-induced neuropathy.
Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; | 2002 |
Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Topics: Action Potentials; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Follow-Up St | 2007 |
Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus.
Topics: Adult; Appetite; Constipation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; | 2000 |
11 other studies available for thalidomide and Dysesthesia
| Article | Year |
|---|---|
Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity.
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Male; Middle Ag | 2013 |
Thalidomide-induced orofacial neuropathy.
Topics: Adult; Face; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Paresthesia; | 2014 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema | 2009 |
[Thalidomide-induced sensory neuropaty in patients with multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Electrodiagnosis; Female; Humans; Male; Middle Aged; Multiple Myelom | 2011 |
[Thalidomide neuropathy].
Topics: Humans; Neuritis; Paralysis; Paresthesia; Peripheral Nervous System Diseases; Thalidomide | 1963 |
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Clinical Trials, Phase | 2005 |
Thalidomide and sensory neurotoxicity: a neurophysiological study.
Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou | 2008 |
Thalidomide neurotoxicity.
Topics: Adult; Aged; Carpal Tunnel Syndrome; Electromyography; Female; Humans; Lupus Erythematosus, Discoid; | 1984 |
Thalidomide-induced perioral neuropathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1997 |
Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report.
Topics: Dermatologic Agents; Drug Administration Schedule; Facial Dermatoses; Female; Fingers; Glucocorticoi | 1998 |
[Huntington's chorea and chronic-progressive spinal muscular atrophy].
Topics: Adult; Anxiety; Arm; Chronic Disease; Female; Functional Laterality; Humans; Huntington Disease; Men | 1966 |